Cervix, Dysplasia, HIV Infections
Conditions
Keywords
Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Fluorouracil, Cervix Dysplasia, Cervix Diseases
Brief summary
To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis in HIV-infected women who have received standard ablative therapy (surgery) for high-grade cervical dysplasia (pre-cancer of the cervix; cervical intraepithelial neoplasia). To correlate time to recurrence of cervical dysplasia with T-cell function. Women with HIV infection are at greater risk for cervical dysplasia. Because of the likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer, there is an urgent need to develop appropriate therapies.
Detailed description
Women with HIV infection are at greater risk for cervical dysplasia. Because of the likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer, there is an urgent need to develop appropriate therapies. Patients are randomized to receive either intravaginal fluorouracil or no treatment (observation only). Fluorouracil cream is self-administered via applicator at biweekly intervals for 6 months. Patients are evaluated for recurrent cervical dysplasia by cytology and colposcopy with or without biopsy.
Interventions
DRUGFluorouracil
Sponsors
Hoffmann-La Roche
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Intervention model
PARALLEL
Primary purpose
PREVENTION
Eligibility
Sex/Gender
FEMALE
Age
13 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Concurrent Medication: Allowed: * Antiretrovirals (AZT, ddI, ddC) and immunomodulators (interferon and interleukin). * Prophylaxis or treatment for opportunistic infections. * Vaginal antifungal agents or other indicated vaginal medications (although not permitted on day of fluorouracil application). * Contraceptives. * Acyclovir (prophylaxis or treatment) in patients with a history of primary or recurrent genital herpes. Patients must have: * HIV infection. * Prior cervical dysplasia (grade II or III cervical intraepithelial neoplasia) successfully treated with an ablative procedure within the past 12 weeks. * Patients less than 18 years of age must have consent of parent or guardian.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Untreated or persistent vaginal or vulvar dysplasia. * Colposcopy or biopsy inconclusive or positive for dysplasia. * Active genital ulcerative disease such as syphilitic chancre or herpes ulcer. * Adenocarcinoma in situ. Concurrent Medication: Excluded: * Cytotoxic chemotherapy for malignancy. * High-dose steroids (\> 10 mg/day prednisone or its steroid equivalent). Patients with the following prior conditions are excluded: * Malignancy requiring cytotoxic chemotherapy within the 3 months prior to study entry. * Prior hysterectomy. * History of allergic reaction or severe hypersensitivity to fluorouracil. Prior Medication: Excluded: * Fluorouracil (systemic or topical) within 3 months prior to study entry.
Countries
Puerto Rico, United States
Outcome results
None listed